about
Polypharmacy in the HIV-infected older adult population.Erectile Dysfunction Among HIV Patients Undergoing Highly Active Antiretroviral Therapy: Dyslipidemia as a Main Risk Factor.Epidemiology and management of antiretroviral-associated cardiovascular disease.A Metabolomics Profiling Study in Hand-Foot-and-Mouth Disease and Modulated Pathways of Clinical Intervention Using Liquid Chromatography/Quadrupole Time-of-Flight Mass SpectrometryCardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America.Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy.Metabolic Disorders in HIV-Infected Adolescents Receiving Protease Inhibitors.The burden of diabetes and hyperlipidemia in treated HIV infection and approaches for cardiometabolic care.Cardiovascular involvements in HIV-infected patients.High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC.Endocrine abnormalities in HIV-infected women are associated with peak viral load - the Children and Women: AntiRetrovirals and Markers of Aging (CARMA) Cohort.Ultraviolet index and location are important determinants of vitamin D status in people with human immunodeficiency virus.Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers.Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons.Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
P2860
Q34037407-C08AC317-0D05-40CD-B3DB-7F2F300DD3BDQ34286607-408DE847-8DB0-44E5-B87D-A69C095F7CBBQ35338096-B75A7801-391E-467B-9A1A-E4FDE62BDBC1Q36663124-237904C0-2B36-478F-BBC5-9DDF9CDBBE3DQ36941650-CE281B29-781D-4598-B666-EDDC94373CAEQ37572266-D862565E-27D6-438A-905B-826D3A078F86Q37673041-EAA9AB0D-5DBE-416E-B280-D116ED95CBC9Q38023235-62BFB823-233A-4A43-A9BB-8B9340968491Q38131061-40F15236-D62C-439E-AD15-3BA61171B280Q38683965-B918DAFB-0CDE-4D8D-B711-154A6C788BCFQ41037315-093E883B-26CD-4CD3-BBE5-42DBD8C8CC8CQ41659730-D32FA7BB-4FA9-4862-BDE5-40A3B54983A5Q42218918-04D47F92-5BDA-46CD-B3A5-26B35E71DF94Q51141761-7E049A0D-F398-4448-B923-53BA02473A08Q55512944-77145CB3-6EC9-4EC4-AA60-3394BE82600F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lipid metabolism in treated HIV Infection.
@en
Lipid metabolism in treated HIV Infection.
@nl
type
label
Lipid metabolism in treated HIV Infection.
@en
Lipid metabolism in treated HIV Infection.
@nl
prefLabel
Lipid metabolism in treated HIV Infection.
@en
Lipid metabolism in treated HIV Infection.
@nl
P1476
Lipid metabolism in treated HIV Infection.
@en
P2093
Joseph J Cadden
Michael P Dubé
P304
P356
10.1016/J.BEEM.2011.04.004
P577
2011-06-01T00:00:00Z